[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ald---alcoholic-liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ald---alcoholic-liver-disease":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,65],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100303037","comparison-of-ald-nash-and-healthy-control-patients-100303037",false,"NCT03224949","Comparison of ALD, NASH, and Healthy Control Patients","Alcoholic Steatosis Patients\n\nInclusion\n\n* Fat accumulation (Steatosis) without signs of fibrosis\u002F inflammation in patients with alcohol abuse (alcohol intake \\>60 g\u002Fday in men and \\>40 g\u002Fday in women)\n* Abnormal liver serum tests indicative of liver disease (elevated AST\\>ALT, y-glutamyl transpeptidase and bilirubin) .\n\nAlcoholic Hepatitis with Mild Fibrosis\n\nInclusion\n\n* Steatosis plus hepatocellular damage (presence of Mallory bodies and hepatocellular ballooning)\n* Polymorphonuclear infiltrate\n* Fibrosis stage 1-2\n\nAlcoholic Hepatitis with Advanced Fibrosis\n\nInclusion\n\n* Steatosis plus hepatocellular damage (presence of Mallory bodies and hepatocellular ballooning)\n* Polymorphonuclear infiltrate\n* Fibrosis stage 3-4.\n\nAlcoholic Cirrhosis\n\nInclusion\n\n* Fibrosis stage 4\n* Presence of complications of cirrhosis such as esophageal varices with our without a previous episode of bleeding, splenomegaly, ascites, hepatic corroborate the diagnosis of cirrhosis.\n\nAlcoholic Cirrhosis with HCC\n\nInclusion\n\n-Diagnostic criteria of cirrhosis and established HCC. The diagnosis of HCC will be established based on histological confirmation or contrast-enhanced radiographic imaging according to the AASLD recommendations.\n\nExclusion\n\n* BMI\\>35\n* HBV\n* Hemochromatosis\n* Wilson's disease\n* Autoimmune hepatitis\n* Drug-inducted liver disease\n* Hepatitis C\n* Antitrypsin deficiency\n* Patients who do not sign informed consent.\n\nNon-alcoholic steatohepatitis\n\nInclusion -Biopsy proven NASH and chronic liver disease due to HCV patients.\n\nExclusion\n\n* Cancer\n* Diabetes\n* Hypertension\n* CAD or stroke\n* Past history of liver disease\n* Hepatitis C\n* Antitrypsin deficiency\n* Alcohol consumption of less than 7 drinks per week for women and less than 14 drinks per week for men\n* BMI \\>35.\n\nHealthy controls\n\nInclusion\n\n-AUDIT-C score less than 4 in men and less than 3 in women.\n\nExclusion\n\n* Cancer (except of non-melanoma skin cancer)\n* Diabetes\n* Hypertension\n* Hypercholesterolemia\n* Coronary artery disease or stroke\n* History of current or past liver disease of any etiology\n* BMI \\>27Kg\u002Fm2",true,"ALL","18 Years","75 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","The availability of biological samples from individuals with alcoholic liver disease (ALD), as well as samples from appropriate heavy drinking, yet healthy controls and non-drinking healthy controls, is an essential first step in the translation of basic research advances to the clinic. The purpose of the Clinical Core component of the P50 Northern Ohio Alcohol Center (NOAC) is to provide biological samples (plasma\u002Fserum, buffy coats, and urine) from patients with different stages of alcoholic liver disease, as well as healthy control subjects, to members of the NOAC. These samples can then be used to test specific hypotheses related to the presence of specific biomarkers in the serum, functional immune activity in PBMCs and\u002For genetic polymorphisms that may predict severity of disease, short- and long-term morbidity and mortality and\u002For responsivity to specific therapeutic interventions commonly used in clinical practice. This study is building on the established biorepositories and the diversity of outstanding clinical expertise at the Cleveland Clinic. This biorepository included clinical samples (plasma, serum, buffy coats, and urine) from patients with different stages of ALD and subjects who are heavy drinkers without ALD, recruited from the Cleveland Clinic alcohol use disorder treatment clinic. This study will be responsible for collecting more data to help build the CCF-ALD biorepository via subject recruitment and communication and specimen collection.",[25],"ALD - Alcoholic Liver Disease","RECRUITING","2025-11-24",{"date":29,"type":30},"2025-12-01","ACTUAL",{"date":32,"type":30},"2017-06-19",{"date":34,"type":21},"2028-09-30",{"name":36,"class":37},"The Cleveland Clinic","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":45,"eligibilityCriteria":46,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":50,"studyType":22,"phases":4,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":38},"100605975","health-literacy-and-self-efficacy-expectations-in-patients-with-alcohol-related-liver-cirrhosis-100605975","NCT07169526","Health Literacy and Self-efficacy Expectations in Patients With Alcohol-related Liver Cirrhosis","Gesundheitskompetenz Und Selbstwirksamkeitserwartung Bei PatientInnen Mit Alkoholbedingter Leberzirrhose","GESA","Inclusion Criteria:\n\n* age (18-99)\n* liver cirrhosis\n\nExclusion Criteria:\n\n* pregnancy\n* insufficient german","99 Years",{"count":49,"type":21},200,"1 Month","The goal of this observational study is to quantify the health literacy and self-efficacy in people with alcohol-related liver cirrhosis.",[53,54,55,25],"Self-Efficacy","Health Literacy","Liver Cirrhosis","2025-09-05",{"date":58,"type":30},"2025-09-11",{"date":60,"type":30},"2025-08-11",{"date":62,"type":21},"2026-10",{"name":64,"class":37},"Hannover Medical School",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":72,"targetDuration":74,"studyType":22,"phases":4,"briefSummary":75,"conditions":76,"keywords":80,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":99},"100585837","long-term-follow-up-to-determine-outcome-in-liver-disease-love-study-100585837","NCT06907563","Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)","LOVE","Inclusion Criteria:\n\n* Previous Informed consent for cohort studies\n* \\> 18 years of age\n* Diagnosis of SLD (MASLD, MetALD, ALD)\n\nExclusion Criteria:\n\n* No consent for previous cohort studies\n* \\\u003C 18 years of age\n* No Diagnosis of SLD (MASLD, MetALD, ALD)",{"count":73,"type":21},30000,"10 Years","The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years. At current limited data on liver-specific and overall outcome in patients with MASLD, MetALD and ALD are available. Liver histology is the only accepted surrogate to reasonably likely predict outcomes in patients with non-cirrhotic liver disease and is currently used in regulatory trials. To overcome the limitations of liver biopsy and use validated non-invasive tests (NITs) to predict outcomes, the LOVE study will be conducted based on existing cohort studies in well pheno- and genotyped patients and will inform on the relevant outcomes based on baseline and ongoing biomarker assessment. The overarching goal is to qualify a NIT for patient identification and preventive measures in the regulatory context.",[77,78,79,25],"Steatotic Liver Disease","MASLD\u002FMASH (Metabolic Dysfunction-Associated Steatotic Liver Disease \u002F Metabolic Dysfunction-Associated Steatohepatitis)","Steatotic Liver Disease of Mixed Origin (MetALD)",[81,82,83,84,85,86,87,88],"MASH","SLD","NITs","MASLD","ALD","MetALD","Metabolism","Liver","NOT_YET_RECRUITING","2025-03-26",{"date":92,"type":30},"2025-04-02",{"date":94,"type":21},"2025-04-15",{"date":96,"type":21},"2035-12-31",{"name":98,"class":37},"Universität des Saarlandes",4]